Abstract:Minatogawa et al. [1] should be commended for conducting this important trial. Antiemetic guidelines devised from the major international organizations recommend now olanzapine as a fixed part of a four-drug prophylactic regimen in the setting of highly emetogenic chemotherapy (HEC) [2, 3]. In light of this, it is clinically relevant that a four-drug regimen containing olanzapine, palonosetron, a neurokinin-1 receptor antagonist, and dexamethasone (DEX) single-dose was shown to be non-inferior to the guideline-recommended reference regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin-based HEC. Also, in the SPARED trial both patients' global health status scores and the incidence of severe nausea were not worsened by DEX sparing beyond day 1. However, the authors failed to take into account the available evidence on the DEX sparing strategy in the cisplatin setting when interpreting the clinical implications of the study results. Despite the SPARED trial met its primary objective to demonstrate non-inferiority of the DEX-sparing arm in terms of complete response (CR) during the delayed phase, the authors did not confirm their study hypothesis that olanzapine 5 mg could substitute for DEX on days 2–4 to prevent delayed CINV following cisplatin. This position relies on the finding that DEX sparing beyond day 1 caused a significant increase in mild to moderate nausea and appetite loss [1]. It is interesting to note that a prior non-inferiority study (LUNG-NEPA trial) showed comparable antiemetic control during the 5 days post-chemotherapy with a three-drug regimen of NEPA (a fixed-dose combination of netupitant and palonosetron) plus DEX single-dose versus the standard reference treatment with 4-day DEX in the setting of high-dose (≥70 mg/m 2 ) cisplatin [4]. Although olanzapine was not used, efficacy results in the DEX-sparing arm are comparable to those seen in the SPARED trial not only in terms of CR rates (primary endpoint) but also rates of patients free of nausea or vomiting. While the patient population is similar between the two studies according to sex and age, only 80% of patients in the SPARED trial received cisplatin at a dose of 70 mg/m 2 or greater. Since olanzapine 5 mg combined with palonosetron, aprepitant, and multiple-day DEX was shown to be better than placebo plus the same standard regimen in patients undergoing cisplatin [5], it is important to underline that we are still lacking of evidence from an adequately powered trial comparing 5 mg with 10 mg olanzapine in the CINV setting [6]. Therefore, there is a question whether olanzapine 5 mg can provide full benefit in improving control of cisplatin-induced nausea when the drug is added to a standard antiemetic regimen with DEX sparing on days 2–4. In the SPARED trial, the results of secondary endpoints suggest that the ability to improve nausea control may be jeopardized when olanzapine 5 mg is administered in combination with the DEX-sparing strategy.

Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy

Phase III Randomized Trial of Palonosetron and Dexamethasone with or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

The Effect of Palonosetron Hydrochloride in the Prevention of Chemotherapy-Induced Moderate and Severe Nausea and Vomiting

Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population

Preventive Effect of Smecta on Delayed Emesis Induced by High Dose Cisplatin Chemotherapy:A Randomized Cross over Study

RS1 (RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter SGLT1.

A Randomized Trial of Ondansetron Combined with Methyprednisolone for Prevention of Emesis Induced by Chemotherapy

Antiemetic Efficacy and Safety of Palonosetron on Days 1 and 5 with Aprepitant and Dexamethasone during Bleomycin, Etoposide, and Cisplatin Chemotherapy in Patients with Germ Cell Tumor: A Prospective Study

Single-dose Tropisetron for prevention of Cisplatin-induced emesis

Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.

Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

Chemoradioprotection of the rat parotid gland by combined use of WR-2721 and Ro-07-0582.

Comparison of Tropisetron Versus Tropisetron Plus Methylprednisolone in Prevention of Chemotherapy Induced Emesis

A Clinical Study of Palonosetron in Prevention of Chemotherapy-related Nausea and Vomiting in Patients with Breast Cancer

Effect of Palonosetron in Preventing Chemotherapy-Induced Vomiting

Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study

Applying palonosetron to prevent nausea and vomiting caused by chemotherapy with nimustine in brain glioma patients

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)

Comment on "Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)"